Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

We recently compiled a list of 11 Best Undervalued Stocks to Invest in Now. Lincoln National Corporation stands third on our ...

Healthcare firm Heartflow said on Friday it was targeting a valuation of up to $1.32 billion in its initial public offering in the United States.

Rounding up five deals in the home healthcare sector, which has caught the attention of Accel-KKR, Berkshire Partners, ...

Lincoln Financial reported strong second-quarter 2025 results that the company said reflects an increasingly diversified earnings mix.

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

UnitedHealth Group Inc. appointed Wayne DeVeydt to become chief financial officer, replacing longtime finance chief John Rex.

The biopharma spinoff will advance the development of its five investigational therapies designed to treat autoimmune disease.

Bristol Myers Squibb and Bain Capital have formed a new independent biopharmaceutical company focused on developing new ...